Citrosteril

Quick links to important sections

Citrosteril

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Citrosteril

Property Description
Active ingredient Citric Acid, Citric Acid Monohydrate
Form Powder for oral solution (sachets/granules)
Pharmacological class Urinary Alkalinizer, Electrolyte Balance Modulator
Common use Systemic pH modulation (urine pH increase)
Origin Derived carboxylic acid

What Type of Medicine is Citrosteril?

Citrosteril is classified as a Urinary Alkalinizer and an Electrolyte Balance Modulator, operating as an oral urologic agent. The active ingredients are the combination preparation of Citric Acid and Citric Acid Monohydrate, utilized primarily as a metabolic precursor. Citrate salts are clinically recognized for their ability to increase urinary pH, which is critical for supporting the health of the urinary system.

This medicine is functionally inert until metabolized by the body, where the Citric Acid is converted into bicarbonate, the powerful alkalinizing agent. This process leads to controlled systemic alkalinization, which subsequently lowers the acidity of the urine. The fundamental purpose of this pH modulation, coupled with the citrate component's role as a chelating agent that binds to calcium ions, is to inhibit the crystallization and precipitation of stone-forming substances. Citrate therapy is a cornerstone in managing the underlying chemical environment that promotes crystal formation. This means the medicine is often used to maintain urinary health in conditions where crystal formation is a recurring risk.

Composition and Form: Powder for Oral Solution

Citrosteril is supplied as a powder for oral solution, commonly packaged in individual sachets or granules, intended exclusively for the oral route of administration. The core composition utilizes the two forms of the acid, Citric Acid and Citric Acid Monohydrate, which are derived carboxylic acids. This dry combination preparation requires mandatory reconstitution with water prior to ingestion, which ensures the components are delivered as an oral solution for efficient absorption and initiation of the systemic pH control effect. This powdered form is a differentiating factor, offering enhanced shelf stability and ease of dosage adjustment compared to some fixed-dose tablets or pre-mixed liquid solutions found in the market.

What side effects are possible with Citrosteril?

Possible Side Effects and Safety Information

Safety characteristics for oral citrate preparations like Citrosteril are officially documented through classifications of adverse reactions by body system and the identification of serious metabolic risks. The safety profile is structured around the consequences of its action as an electrolyte and acid-base modulator.

Adverse Reactions and System-Organ Classes

The most frequently reported effects in clinical experience fall under Gastrointestinal Disorders. These generally include common, non-serious complaints such as abdominal discomfort, nausea, vomiting, diarrhea, and loose bowel movements.

More significant risks are associated with the Metabolism and Nutrition Disorders system. These serious adverse reactions include the potential for hyperkalemia (elevated potassium levels), which can be fatal, and the development of systemic alkalosis (excessive blood alkalinity), particularly in individuals with compromised renal mechanisms. Regulatory documents also note the risk of severe gastrointestinal lesions, including ulceration and hemorrhage, associated with concentrated oral salt preparations.

Population-Specific Safety Constraints

Official labeling defines specific safety constraints for high-risk groups. Patients with severe renal impairment (a glomerular filtration rate of less than 0.7 mL/kg/min) face an increased danger of hyperkalemia and soft tissue calcification. Furthermore, the safety and effectiveness of this class of medicine have not been established in the pediatric population.

Safety-Related Restrictions

Regulatory restrictions limit use in patients with conditions that predispose to hyperkalemia (e.g., untreated Addison's disease). Concurrent use is restricted with certain medications, including potassium-sparing diuretics (due to the risk of severe hyperkalemia) and aluminum-based antacids.

Overdose and Emergency Response

Overdose with oral citrate preparations, classified as a urinary alkalinizer, is officially documented as primarily leading to severe systemic Metabolic Alkalosis. This profound shift in the body’s acid-base balance can trigger specific clinical manifestations listed in regulatory labeling. These include the neuromuscular symptoms of Paresthesia (tingling) and Tetany (muscle spasms), along with generalized Muscle Weakness and Lethargy.

A critical physiological finding associated with overdose is Hypocalcemia (low serum calcium levels), which results from the citrate component binding to calcium, potentially leading to severe Cardiovascular Manifestations. Authorities note that patients with Impaired Renal Function carry an officially documented increased risk of severe outcomes, particularly dangerous electrolyte abnormalities like Hyperkalemia or Hypernatremia.

Immediate Medical Attention is officially required upon any suspected overdose. Due to the serious risk of electrolyte and metabolic disturbances, regulatory guidance mandates that patients Seek Immediate Medical Attention and may require specialized Hospital Monitoring. Management is strictly Symptomatic and Supportive, as the regulatory documents confirm that No Specific Antidote is Known for this type of preparation.

Therapeutic Uses of Citrosteril

The primary role of this oral citrate preparation, classified as a urinary alkalinizer, is to address symptoms related to systemic imbalance. It is commonly used across domains where additional symptomatic support is needed for conditions marked by temporary physiological imbalance.

This therapeutic category is relevant for easing symptoms associated with recurrent kidney stone formation and chronic metabolic disorders. The preparation is generally used for managing specific conditions, including uric acid nephrolithiasis, calcium oxalate stones where low urine pH is a factor, and certain forms of chronic metabolic acidosis such as renal tubular disorders.

Preventing and Dissolving Uric Acid Kidney Stones

This preparation is applied across domains where additional symptomatic support is needed for conditions presenting with acute or recurrent manifestations, specifically nephrolithiasis (kidney stone formation). It is relevant for managing symptoms related to physical discomfort that arise from stones. By chemically altering the urine to become less acidic, this medication provides support that helps ease the overall symptom burden by inhibiting the crystallization and growth of stone-forming substances. This preventative action is considered relevant for patients prone to recurrent stone episodes and may assist with the active dissolution (litholysis) of existing uric acid stones.

Supporting Management of Chronic Metabolic Acidosis

The preparation is applicable within clinical settings that involve acute or disruptive symptom patterns related to systemic acid imbalance. It is commonly used across conditions characterized by periods of heightened symptoms, such as renal tubular disorders. The medication is relevant for managing symptoms related to systemic imbalance that create noticeable physiological strain. It provides a long-term benefit by helping to restore the overall acid-base balance in the body, which is considered relevant for patients with chronic conditions.


Quick Fact: Relief for Recurrent Nephrolithiasis Risk This medicine is commonly used to help manage the underlying chemical causes of stone formation, contributing to improved comfort during symptomatic periods.

Regulatory References

  1. DailyMed (NIH) drug label for Potassium Citrate

Eligibility and Restrictions for Use

Who Can and Cannot Use Citrosteril?

Citrosteril (Citric Acid/Citrate salts) is subject to strict population eligibility rules defined by government regulatory bodies. Use is generally established for adults addressing specific kidney stone formations but is defined by several absolute contraindications based on metabolic and physiological risk.

The medicine must not be used by any patient with conditions that prevent the safe excretion of potassium or compromise the digestive tract. These include: severe renal impairment (e.g., oliguria, azotemia), hyperkalemia (high blood potassium levels), untreated adrenal insufficiency, and severe myocardial damage or heart failure. It is also strictly contraindicated for individuals with an active urinary tract infection, peptic ulcer disease, or those concurrently using a potassium-sparing diuretic.

Regulatory agencies state that the safety and effectiveness in children have not been established. For pregnancy and lactation, administration is restricted and must occur only if clearly needed. Use requires caution in the elderly and in patients with hepatic failure or hypertension.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding Citrosteril indicates that the product is a thermochemical disinfection agent used exclusively for the cleaning and decalcification of haemodialysis machines and related equipment. It is not a systemic human medication, and therefore, regulatory documents do not contain standard drug-drug, drug-food, or drug-alcohol interaction data relevant to human pharmacokinetics.

The regulatory profile for this product is focused on procedural constraints to ensure safety and chemical compatibility within the medical device system.


Official Regulatory Interaction Profile

Interaction Entity Official Regulatory Data (Human Systemic Context)
Drug-Drug Interactions (Pharmacokinetic/Pharmacodynamic) None documented. The product does not enter the human systemic circulation.
Food, Alcohol, or Herbal Interactions None documented.
Contraindicated Combinations (Human Use) None documented.
Procedural Constraints Required Rinsing/Elimination Steps.

The primary regulatory constraint linked to its use is the requirement for the machine's fluid pathways to undergo a complete and thorough rinsing cycle immediately following disinfection. This step is mandated to eliminate all chemical residue (citric acid, lactic acid, and malic acid) before the machine is connected to a patient for treatment, thereby preventing any unintended chemical exposure or interference with human bodily functions or co-administered medicinal products.

Mechanism of Action

Citrosteril, a thermochemical disinfectant solution, contains citric acid, lactic acid, and malic acid as its primary active components. The mechanism of action is mediated by a synergistic effect of these organic acids, primarily targeting microbial cellular components and inorganic mineral deposits.

At the operational pH of 1.7 to 2.0 and elevated temperature (typically 84 C), the acid components induce denaturation of microbial proteins and enzymes across bacteria, fungi, and viruses. The low pH environment causes significant acid stress, disrupting the integrity of the cell membrane and cell wall, leading to loss of homeostasis and eventual cellular lysis. Specifically, the organic acids act as proton carriers across the microbial membrane, decreasing the intracellular pH and inhibiting crucial metabolic pathways and nucleic acid synthesis required for replication and survival. Simultaneously, the acidic solution facilitates decalcification by chelating and dissolving calcium carbonate ( CaCO3) and other mineral salts, preventing the formation of biofilm matrices that shield microorganisms from disinfection.

Dosage and Administration Information

How to Use Citrosteril: Administration Guidelines

This section describes the administration principles for Citrosteril, a urinary alkalinizer.


Administration Scope

The approved route for this preparation is Oral. The medicine is provided as a powder or granules intended to be reconstituted into an oral solution. Dosing is measured in milliequivalents (mEq) of bicarbonate equivalent, reflecting the metabolic effect of the citrate components. Standard adult dosing typically ranges from 30 mEq to 60 mEq per day, divided and administered in two to four doses throughout the day. The total daily dosage must not exceed 100 mEq. For pediatric use, dosages are lower and determined by a healthcare provider.


Procedural Administration Requirements

Preparation: Administration requires that the prescribed amount of powder or concentrate be adequately diluted by mixing with a full glass of water or other liquid before ingestion. This step is a mandatory procedural constraint to mitigate potential gastrointestinal irritation associated with concentrated salt preparations.

Timing: The diluted solution must be consumed with or immediately after meals or with a bedtime snack. This scheduled intake, often administered two or more times per day, is essential for maintaining a continuous alkaline urinary environment over a 24-hour period.

Titration: The final maintenance dose is not fixed but is titrated (adjusted) based on periodic monitoring of the patient’s 24-hour urinary pH levels. This is done to achieve the desired therapeutic range, commonly a urinary pH between 6.0 and 7.0. The use of this medicine is generally a long-term maintenance protocol.


Recent Clinical Evidence

Research Evidence / Overview of Studies for Citrosteril

Evidence for Use in Recurrent Kidney Stone Formation

The research on oral citrate preparations has primarily evaluated its application in the context of recurrent stone formation, specifically for stones related to acidic urine and low citrate levels. Studies, including Randomized Controlled Trials (RCTs) and systematic reviews, generally included adults with a history of stone formation. Research examined how changes in urinary biomarkers—such as pH and citrate levels—relate to the risk of developing new stones or the stability of existing stones. Findings describe patterns where the use of citrate preparations was associated with both increased urinary pH and elevated urinary citrate levels. Some trials described patterns related to a change in the rate of new stone formation compared to control groups over follow-up periods, although findings were mixed across systematic reviews regarding the consistency of these patterns.

Evidence for Use in Chronic Metabolic Acidosis

The use of this type of alkali preparation has also been evaluated in the context of chronic metabolic acidosis, a clinical situation studied by researchers where the body has difficulty maintaining acid-base balance. The evidence base includes RCTs and established clinical guidelines. Studies focused on systemic imbalances associated with conditions like chronic kidney disease (CKD) or renal tubular acidosis (RTA). Research examined whether the preparation could restore and maintain normal serum bicarbonate levels. Findings highlighted changes measured during the study period where administration was associated with increased serum bicarbonate. Studies also monitored how functional endpoints, such as the rate of change in eGFR, evolved over observation periods. The evidence is often reflected in authoritative clinical consensus for these conditions.

Long-Term Studies and Evidence in Specific Patient Groups

Clinical research for both indications often involves observation periods ranging from six months to several years. While these durations provide intermediate data, long-term outcomes regarding stone recurrence prevention are not uniformly established. Management of acid-base balance is continuous, meaning that studies provide context, but long-term durability of the response is an area of ongoing study. Research has predominantly focused on adults with diagnosed conditions. Few data are available concerning the long-term kidney outcomes in pediatric populations with RTA, and follow-up durations were limited for understanding the full impact on older adults.

What Is Still Uncertain about the Research Evidence

Despite the existence of controlled trials, there are areas where the evidence base remains limited, meaning certainty remains low. One limitation is the variation in evidence quality across studies, which makes it difficult to draw uniform conclusions. Subgroup findings are uncertain, meaning there is limited information on how specific patient characteristics might influence the patterns observed. The research so far indicates that head-to-head comparative evidence against all other alkali agents or placebo for every outcome studied is limited. Furthermore, the optimal dosing regimen for long-term use across all patient groups is not fully established in the research, and more studies are ongoing.

Key Studies & References

  1. Potassium Citrate: Treatment and Prevention of Recurrent Calcium Nephrolithiasis (Meta-analysis of four trial studies on citrate therapy)
  2. Oral Bicarbonate Therapy in Non-Haemodialysis Dependent Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
  3. KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease (Metabolic Acidosis Guideline)

Frequently Asked Questions (FAQ)

Common questions about Citrosteril (FAQ)


Q: How quickly does Citrosteril usually start to work?

A: The active components of this medicine are quickly absorbed and processed by the body to produce bicarbonate, a metabolic agent. The onset of the metabolic process, which creates the desired change in urinary acidity ( pH), is generally considered to be prompt. Official administration guidelines focus on taking the medicine consistently to maintain a continuous alkaline state.


Q: Is it possible for Citrosteril to interact with common pain relievers?

A: Official regulatory information restricts concurrent use with certain medications, such as aluminum-based antacids. While specific common pain relievers are not uniformly cited on all labels, the concentrated salt preparation carries an officially documented risk of gastrointestinal irritation. It is important that a healthcare provider is informed of all medications being taken.


Q: Can Citrosteril be taken with a multivitamin?

A: Regulatory documents do not typically specify interactions with every type of multivitamin. However, because this medicine affects pH and acts as a chelating agent (it binds to certain ions), it has the potential to interfere with the absorption of other oral agents, particularly those containing minerals like iron. The principle of taking it separately from other oral supplements may be a consideration.


Q: Can taking Citrosteril cause changes in appetite?

A: A direct change in appetite is not typically listed as a frequent side effect in official documents. However, the most commonly reported adverse effects are gastrointestinal issues, including nausea, vomiting, and abdominal discomfort. These reported effects could potentially influence a person's desire to eat.


Q: Do researchers know the full extent of Citrosteril's potential interactions?

A: Research documents indicate that clinical evidence comparing this medication to all other alkali agents is limited. Additionally, the optimal dosing regimen for long-term use across all patient groups is not fully established. Therefore, the completeness of interaction data across every possible combination is an area where knowledge continues to develop.


Q: Can Citrosteril interact with herbal supplements?

A: Official regulatory documents primarily focus on established drug-drug interactions, and generally, no specific interactions with herbal products are documented in the regulatory profile for this preparation.


Q: How is Citrosteril different from other drugs used for similar conditions?

A: Citrosteril is classified as a Urinary Alkalinizer and an Electrolyte Balance Modulator. Its therapeutic action is to increase the pH (reduce the acidity) of the urine by converting its citrate components into bicarbonate in the body. This is a mechanism that is distinct from medicines that only act as antibiotics or diuretics for similar conditions.


Q: Does Citrosteril have an effect on liver function?

A: Official pharmacology documentation indicates that the active ingredient, citrate, is metabolized in the liver as part of its conversion to bicarbonate. Studies have noted that reduced clearance of citrate is observed in patients with severely impaired liver function, highlighting the liver's role in the body's processing of the medication.


Q: What happens if a person misses a scheduled dose of Citrosteril?

A: Patient instructions found in regulatory documents typically recommend taking the missed dose as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to return to the regular schedule. The instructions typically advise against taking a double dose to compensate for a missed one.


Q: Can Citrosteril cause an allergic reaction?

A: As with most medications, allergic reactions or hypersensitivity are possible, though rare. Safety information advises that signs of a serious allergic reaction, such as difficulty breathing, hives, or swelling of the face, require immediate medical attention.


Q: What kind of research evidence is there to support the use of Citrosteril?

A: Clinical studies and official indications support the use of citrate preparations for two primary purposes: managing the underlying chemical environment that promotes recurrent kidney stone formation, and managing chronic metabolic acidosis. Research examines its ability to safely maintain serum bicarbonate levels and increase urinary pH.


Q: Does the time of day a person takes Citrosteril matter?

A: Official administration guidelines mandate that the diluted solution be consumed with or immediately after meals or with a bedtime snack. This specific timing is considered necessary for maintaining a continuous alkaline urinary environment over a 24-hour period, which is the therapeutic goal.


Q: Are there any long-term side effects associated with Citrosteril use?

A: The medicine is frequently prescribed as a long-term maintenance protocol. Regulatory documents highlight that for patients with specific health conditions, regular blood and urine tests are required to monitor for serious long-term metabolic risks, particularly excessive potassium (hyperkalemia) and systemic alkalinity (alkalosis).


Q: Does Citrosteril contain lactose or gluten?

A: The official product labeling requires the disclosure of both active and inactive ingredients (excipients). Information regarding the presence of common allergens or fillers like lactose or gluten can be found in the product-specific inactive ingredient section of the regulatory drug label.


Q: What are the signs of a serious, though rare, reaction to Citrosteril?

A: Serious reactions that should be reported immediately relate to severe electrolyte imbalances. This includes signs of hyperkalemia (e.g., muscle weakness, tiredness, irregular heartbeat) or signs of systemic alkalosis (e.g., mood changes, confusion, muscle twitching), as described in patient safety information.


Q: Can Citrosteril affect the results of any lab tests?

A: Yes. Regulatory documents require that patients taking this medicine undergo periodic examinations of serum electrolytes, particularly blood bicarbonate levels. This is because the medicine is designed to intentionally alter the body's acid-base balance, which is monitored via these lab tests.


Q: Is there a generic version of Citrosteril available?

A: The active ingredients in the medicine are citric acid and sodium citrate, a combination that has been available for many years. Numerous generic formulations of this specific combination are available in the market under various brand names.


Q: What does the patient information leaflet say about alcohol and Citrosteril?

A: Official patient information sheets for this preparation often state that no specific interactions with alcohol are documented in the regulatory profile. As with any medication, caution regarding alcohol consumption is typically suggested.


Q: Do studies suggest Citrosteril is generally well-tolerated?

A: Studies confirm that the most frequent side effects reported are common but non-serious gastrointestinal complaints, such as stomach upset or diarrhea. This pattern suggests that, for the majority of patients, the medicine is generally well-tolerated from a systemic safety perspective.


Q: Is Citrosteril known to cause dizziness or lightheadedness?

A: Dizziness and lightheadedness are not typically listed among the most frequent side effects, which are primarily gastrointestinal issues. However, these effects are sometimes noted under the less common or unknown incidence categories of adverse effects associated with this type of medicine.


Q: Is it safe to drive or operate machinery while taking Citrosteril?

A: Official labels generally do not contain a direct statement restricting driving. Official guidance suggests that if adverse reactions, such as dizziness, are experienced, caution should be exercised before operating machinery or driving.


Q: Why would a doctor switch a patient from a different drug to Citrosteril?

A: The therapeutic goal of this medicine is to maintain urinary pH at a specific therapeutic range or to manage metabolic acidosis. A switch may occur if the previous treatment did not effectively achieve the targeted urinary pH or if a different salt form (such as the sodium-based salt) is deemed necessary for the patient's overall management plan.


Q: What is the shelf life of Citrosteril?

A: The specific shelf life (expiration date) for the medicine is determined by the manufacturer based on product stability data and is documented on the product's container. Regulatory guidelines mandate that the product be stored at a controlled room temperature to maintain this stability until the expiration date.


Q: Is Citrosteril considered a high-risk medication?

A: The medicine does not carry a Black Box Warning, nor is it universally classified as a High-Alert Medication. However, it is officially considered high-risk for specific patient groups, such as those with severe renal impairment, due to the serious potential for fatal electrolyte imbalances.


Q: Does Citrosteril need to be taken with food?

A: Yes, official administration guidelines require the diluted solution to be consumed with or immediately after meals or with a bedtime snack. This is a procedural constraint intended to minimize the potential for the concentrated salt preparation to cause gastrointestinal irritation.


Q: Is there a maximum time a person can safely take Citrosteril?

A: This medicine is frequently prescribed for long-term maintenance protocols in conditions like recurrent kidney stone formation, and clinical studies often involve observation periods of several years. There is no uniformly established maximum duration, but continuous laboratory monitoring of electrolyte levels is mandatory for all long-term use.


Q: Is Citrosteril considered a first-line treatment for its primary indication?

A: For its primary indication—managing the underlying chemical environment that promotes crystal formation—citrate therapy is described in authoritative reviews from organizations like the NIDDK as a cornerstone of management. This suggests that it holds a high and established standing in clinical guidelines for that purpose.

How should Citrosteril be stored and disposed of?

The storage and disposal of Citrosteril (Citric Acid Monohydrate powder) must strictly adhere to the requirements documented in official regulatory labeling.

Storage Requirements

Citrosteril must be stored at controlled room temperature, typically between 15, C and 25, C, in a cool, dry, and well-ventilated place to maintain the product's stability. The container must be kept tightly closed to protect the powder from moisture. Regulatory documents mandate that the product must be stored out of the reach of children and locked up (P405) to ensure safety. Storage areas must also be kept away from incompatible materials, such as strong bases or oxidizing agents.

Disposal Instructions

Disposal of unused or expired product and its container must be in accordance with local, regional, and national regulations (P501). It is explicitly required not to let the product enter drains, surface, or ground water, as specified in the environmental precautions. The product should be disposed of via an approved waste disposal plant.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Citrosteril found in:

A-Z Index: